Methanesulfonamide, N-[2-[[4-[3-[(1-methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]-, methanesulfonate (1:1)
| Title | Journal |
|---|---|
| Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry letters 20131215 |
| Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. | Bioorganic & medicinal chemistry 20130401 |
| Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20120615 |
| Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. | European journal of medicinal chemistry 20120501 |
| Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. | Colloids and surfaces. B, Biointerfaces 20120201 |
| Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. | Colloids and surfaces. B, Biointerfaces 20111201 |
| Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors. | European journal of medicinal chemistry 20111001 |
| Rilpivirine: a step forward in tailored HIV treatment. | Lancet (London, England) 20110716 |
| The home as an appropriate setting for women undertaking cervical ripening before the induction of labour. | Midwifery 20110201 |
| Colloid formation by drugs in simulated intestinal fluid. | Journal of medicinal chemistry 20100527 |
| Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1). | Mini reviews in medicinal chemistry 20100101 |
| [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1]. | Yao xue xue bao = Acta pharmaceutica Sinica 20090401 |
| Systematic review: Helicobacter pylori infection and impaired drug absorption. | Alimentary pharmacology & therapeutics 20090215 |
| A study of 3-substituted benzylidene-1,3-dihydro-indoline derivatives as antimicrobial and antiviral agents. | Zeitschrift fur Naturforschung. C, Journal of biosciences 20090101 |
| Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine. | Bioorganic & medicinal chemistry 20080401 |
| Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay. | Analytical biochemistry 20080301 |
| Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. | Health services research 20080201 |
| [HIV-1 genotypic resistance profiles in children failing highly active antiretroviral therapy]. | Zhonghua yi xue za zhi 20071211 |
| US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference? | Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20070801 |
| Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. | International journal of pharmaceutics 20070801 |
| Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. | Protein science : a publication of the Protein Society 20070801 |
| Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India. | AIDS research and human retroviruses 20070501 |
| Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. | HIV clinical trials 20070101 |
| Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061215 |
| Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. | AIDS (London, England) 20060424 |
| Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. | Journal of medicinal chemistry 20060420 |
| Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. | AIDS research and human retroviruses 20060301 |
| Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. | The American journal on addictions 20060101 |
| Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. | Clinical pharmacokinetics 20050101 |
| Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20041101 |
| [Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)]. | Yao xue xue bao = Acta pharmaceutica Sinica 20040801 |
| Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children. | AIDS (London, England) 20040702 |
| Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. | The Journal of antimicrobial chemotherapy 20040701 |
| New 3-O-acyl betulinic acids from Strychnos vanprukii Craib. | Journal of natural products 20040601 |
| Clinical utility of current NNRTIs and perspectives of new agents in this class under development. | Antiviral chemistry & chemotherapy 20040501 |
| Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. | The Journal of infectious diseases 20040401 |
| In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results. | The new microbiologica 20040401 |
| Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). | Psychosomatics 20040101 |
| Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. | AIDS (London, England) 20031205 |
| Pfizer announces free drug program. | AIDS patient care and STDs 20030901 |
| Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1. | AIDS (London, England) 20030613 |
| Protease inhibitor-sparing regimens: new evidence strengthens position. | Journal of acquired immune deficiency syndromes (1999) 20030601 |
| Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. | Seminars in liver disease 20030501 |
| Pharmacia pilots patent share for HIV drug. | Nature reviews. Drug discovery 20030401 |
| Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. | Journal of clinical pharmacology 20030201 |
| Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. | Journal of virology 20030101 |
| Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. | British journal of clinical pharmacology 20030101 |
| Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants. | Journal of medicinal chemistry 20021219 |
| Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. | Clinical pharmacology and therapeutics 20021201 |
| Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy. | AIDS (London, England) 20020906 |
| Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. | The Journal of infectious diseases 20020901 |
| Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020705 |
| Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. | Pharmaceutical research 20020701 |
| Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. | The American journal of medicine 20020415 |
| Determination of delavirdine in very small volumes of plasma by high-performance liquid chromatography with fluorescence detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020405 |
| Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors. | AIDS (London, England) 20020329 |
| Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. | Current pharmaceutical design 20020101 |
| Delavirdine in rescue regimens. | TreatmentUpdate 20020101 |
| Drugs for HIV infection. | The Medical letter on drugs and therapeutics 20011126 |
| Synthesis and anti-HIV-1 activity of new delavirdine analogues carrying arylpyrrole moieties. | Chemical & pharmaceutical bulletin 20011101 |
| Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). | Bioorganic & medicinal chemistry letters 20010903 |
| Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. | Therapeutic drug monitoring 20010801 |
| Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. | Virology 20010705 |
| International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. | Journal of acquired immune deficiency syndromes (1999) 20010301 |
| Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. | Bioorganic & medicinal chemistry letters 20010226 |
| Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. | Drug metabolism and disposition: the biological fate of chemicals 20010101 |
| Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. | Journal of clinical pharmacology 20010101 |
| Delavirdine: clinical pharmacokinetics and drug interactions. | Clinical pharmacokinetics 20010101 |
| A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. | Archives of virology 20010101 |
| A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. | HIV clinical trials 20010101 |
| Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations. | HIV clinical trials 20010101 |
| Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. | Clinical pharmacokinetics 20010101 |
| Can delavirdine substitute for ritonavir? | TreatmentUpdate 20010101 |
| Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. | AIDS research and human retroviruses 20000410 |
| Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives. | Journal of medicinal chemistry 20000309 |
| Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). | Antimicrobial agents and chemotherapy 20000301 |
| Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry letters 20000117 |
| Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. | AIDS (London, England) 19990820 |
| Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. | Bioorganic & medicinal chemistry letters 19990607 |
| Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV. | Journal of medicinal chemistry 19980924 |
| A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152. | The Journal of general virology 19980601 |
| Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine). | Biochemical pharmacology 19980301 |
| Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors. | Antiviral chemistry & chemotherapy 19980301 |
| In-vitro selection of HIV-1 variants resistant to non-nucleoside reverse transcriptase inhibitors in monocyte-derived macrophages. | The Journal of antimicrobial chemotherapy 19971201 |
| Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. | Journal of virology 19971101 |
| Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. | Antimicrobial agents and chemotherapy 19970501 |
| Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. | Antiviral research 19970301 |
| Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors. | Journal of medicinal chemistry 19960913 |
| Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. | Molecular pharmacology 19960801 |
| Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s. | FEBS letters 19950814 |
| Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives). | Proceedings of the National Academy of Sciences of the United States of America 19950606 |
| Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | FEBS letters 19950213 |
| In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha. | The Journal of infectious diseases 19950101 |
| Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. | Biochemical pharmacology 19940601 |
| Anti-human immunodeficiency virus type 1 activities of novel non-nucleoside reverse transcriptase inhibitors. | The Journal of antimicrobial chemotherapy 19940201 |
| Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. | Antimicrobial agents and chemotherapy 19940201 |
| A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. | Proceedings of the National Academy of Sciences of the United States of America 19930515 |
| Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate. | Journal of medicinal chemistry 19930514 |
| U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. | Antimicrobial agents and chemotherapy 19930501 |